BAY-405

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBAY-405
Drug Alias NameBAY-405
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 1 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsMitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBayer Pharm AgGerman Cancer Research Center (Dkfz)
China Registration ClassN/A

Develop Information

Active CompaniesBayer Pharm AgGerman Cancer Research Center (Dkfz)
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A